Treatment regimen for metastatic colorectal cancer

Metastatic colorectal cancer with the BRAF V600E mutation has a poor prognosis. An open-label, phase III trial enrolled 665 patients who had disease progression after previous regimens. Patients were randomly assigned to receive encorafenib, binimetinib and cetuximab (triple therapy), encorafenib and cetuximab (double therapy) or cetuximab and irinotecan or cetuximab and FOLFIRI (folinic acid, fluorouracil and irinotecan) (control group). Median overall survival was 9.0 months in the triple-therapy group, 8.4 months in the double-therapy group and 5.4 months in the control group. Response rate was 26% in the triple-therapy group and 2% in the control group.


Original article

  1. Kopetz, S. et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N. Engl. J. Med. (2019)

    Article  PubMed  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Isobel Leake.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Leake, I. Treatment regimen for metastatic colorectal cancer. Nat Rev Gastroenterol Hepatol 16, 706 (2019).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing